Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion

Oncogene volume 23, pages 5577–5585 (2004)Cite this article

Abstract

The Rho family GTPases Rac1, RhoA and Cdc42 function as molecular switches that transduce intracellular signals regulating multiple cell functions including gene expression, adhesion, migration and invasion. p53 and its regulator p19Arf, on the other hand, are tumor suppressors that are critical in regulating cell cycle progression and apoptosis. Previously, we have demonstrated that the Rho proteins contribute to the cell proliferation, gene transcription and migration phenotypes unleashed by p19Arf or p53 deletion in primary mouse embryo fibroblasts (MEFs). To further investigate their functional interaction in the present study, we have examined the involvement of Rho signaling pathways in p53-mediated cell invasion. We found that in primary MEFs (1) p53 or p19Arf deficiency led to a marked increase in the number of focal adhesion plaques and fibronectin production, and RhoA, Rac1 and Cdc42 contribute to the p53- and p19Arf-mediated focal adhesion regulation, but not fibronectin synthesis; (2) although endogenous Rac1 activity was required for the p19Arf or p53 deficiency-induced migration phenotype, hyperactive Rho GTPases could not further enhance cell migration, rather they suppressed cell–cell adhesion of p53−/− MEFs; (3) expression of the active mutant of RhoA, Rac1 or Cdc42, but not Ras, promoted an invasion phenotype of p53−/−, not p19Arf−/−, cells; (4) although ROCK activation can partially recapitulate Rho-induced invasion phenotype, multiple pathways regulated by RhoA, in addition to ROCK, are required to fully cooperate with p53 deficiency to promote cell invasion; and (5) extracellular proteases produced by the active RhoA-transduced cells are also required for the invasion phenotype of p53−/− cells. Combined with our previous observations, these results strongly suggest that mitogenic activation of Rho family GTPases can cooperate with p53 deficiency to promote primary cell invasion as well as transformation and that multiple signaling components regulated by the Rho proteins are involved in these processes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Alexandrova A, Ivanov A, Chumakov P and Vasiliev J . (2000). Oncogene, 19, 5826–5830.

  • Aznar S and Lacal JC . (2001). Cancer Lett., 165, 1–10.

  • Bar-Sagi B and Hall A . (2000). Cell, 103, 227–238.

  • Bernards R and Weinberg RA . (2002). Nature, 418, 823.

  • Bishop AL and Hall A . (2000). Biochem. J., 348, 241–255.

  • Boettner B and Van Aelst L . (2002). Gene, 286, 155–174.

  • Clark EA, Golub TR, Lander ES and Hynes RO . (2000). Nature, 406, 532–535.

  • Comer KA, Dennis PA, Armstrong L, Catino JJ, Kastan MB and Kumar CC . (1998). Oncogene, 16, 1299–1308.

  • Etienne-Manneville S and Hall A . (2002). Nature, 420, 629–635.

  • Fritz G, Just I and Kaina B . (1999). Int. J. Cancer, 81, 682–687.

  • Fujisawa K, Madaule P, Ishizaki T, Watanabe G, Bito H, Saito Y, Hall A and Narumiya S . (1998). J. Biol. Chem., 273, 18943–18949.

  • Gadea G, Lapasset L, Gauthier-Rouviere C and Roux P . (2002). EMBO J., 21, 2373–2382.

  • Gloushankova N, Ossovskaya V, Vasiliev J, Chumakov P and Kopnin B . (1997). Oncogene, 15, 2985–2989.

  • Guo F and Zheng Y . (2004). Mol. Cell. Biol., 24, 1426–1428.

  • Guo F, Gao Y, Wang L and Zheng Y . (2003a). J. Biol. Chem., 278, 14414–14419.

  • Hahn WC and Weinberg RA . (2002). Nat. Rev. Cancer, 2, 331–341.

  • Iotsova V and Stehelin D . (1996). Cell Growth Differ., 5, 629–634.

  • Kaibuchi K, Kuroda S, Fukata M and Nakagawa M . (1999). Curr. Opin. Cell Biol., 11, 591–596.

  • Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G and Sherr CJ . (1997). Cell, 91, 649–659.

  • Levine AJ . (1997). Cell, 88, 323–331.

  • Liliental J, Moon SY, Lesche R, Mamillapalli R, Gavrilova N, Zheng Y, Sun H and Wu H . (2000). Curr. Biol., 10, 401–404.

  • Lin R, Cerione RA and Manor D . (1999). J. Biol. Chem., 274, 23633–23641.

  • Mira JP, Benard V, Groffen J, Sanders LC and Knaus UG . (2000). Proc. Natl. Acad. Sci. USA, 97, 185–189.

  • Mukhopadhyay D, Tsiokas L and Sukhatme VP . (1995). Cancer Res., 55, 6161–6165.

  • Nobes C and Hall A . (1999). J. Cell Biol., 144, 1235–1245.

  • Preudhomme C, Roumier C, Hildebrand MP, Dallery-Prudhomme E, Lantoine D, Lai JL, Daudignon A, Adenis C, Bauters F, Fenaux P, Kerckaert JP and Galiegue-Zouitina S . (2000). Oncogene, 19, 2023–2032.

  • Ridley AJ . (2001). J. Cell Sci., 114, 2713–2722.

  • Sablina AA, Chumakov PM and Kopnin BP . (2003). J. Biol. Chem., 278, 27362–27371.

  • Sahai E, Alberts AS and Treisman R . (1998). EMBO J., 17, 1350–1361.

  • Sahai E and Marshall CJ . (2002). Nat. Rev. Cancer, 2, 133–142.

  • Sahai E and Marshall CJ . (2003). Nat. Cell Biol., 5, 711–719.

  • Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM and Lowe SW . (2002). Cancer Cell, 1, 289–298.

  • Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M and Lengyel E . (2000). Oncogene, 19, 3013–3020.

  • Schwartz MA and Shattil SJ . (2000). Trends Biochem. Sci., 25, 388–391.

  • Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW . (1997). Cell, 88, 593–602.

  • Sherr CJ . (2001). Nat. Rev. Mol. Cell. Biol., 2, 731–737.

  • Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE and Cheung HS . (1999). J. Biol. Chem., 274, 11535–11540.

  • Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H and Fukumoto M . (1998). Br. J. Cancer, 77, 147–152.

  • Van Aelst L and D'Souza-Schorey C . (1997). Genes Dev., 11, 2295–2322.

  • Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ . (2000). Genes Dev., 14, 981–993.

  • Zheng Y . (2001). Trends Biochem. Sci., 26, 724–732.

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF . (1998). Genes Dev., 12, 2424–2433.

  • Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL and Der CJ . (1998). Oncogene, 17, 1415–1438.

Download references

Acknowledgements

We thank Dr Martine Roussel (St Jude Children's Research Hospital) for the gifts of MEFs and Arf cDNA. This work was supported in part by a grant from National Institutes of Health (CA105117).

Author information

Authors and Affiliations

  1. Division of Experimental Hematology, Children's Hospital Research Foundation, University of Cincinnati, Cincinnati, 45229, OH, USA

    Fukun Guo & Yi Zheng

Authors
  1. Fukun Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi Zheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guo, F., Zheng, Y. Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 23, 5577–5585 (2004). https://doi.org/10.1038/sj.onc.1207752

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207752

Keywords

This article is cited by

Search

Advanced search

Quick links